糖皮质激素联合贝复舒滴眼液治疗流行性角结膜炎的临床疗效及其安全性  

Clinical efficacy and safety of glucocorticoid combined with befushu eye drops for epidemic keratoconjunctivitis

作　　者：吴海艳 WU Hai-yan(Sheyang Renai ENT Hospital, Yancheng 224300, China)

机构地区：[1]射阳仁爱耳鼻喉医院,江苏省盐城市224300

出　　处：《临床合理用药杂志》2019年第12期47-48,共2页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的探讨糖皮质激素联合贝复舒滴眼液治疗流行性角结膜炎(EKC)的临床疗效及其安全性。方法选取射阳仁爱耳鼻喉医院眼科2017年收治的EKC患者75例,采用随机数字表法分为对照组37例和观察组38例。对照组患者在常规治疗基础上给予糖皮质激素妥布霉素地塞米松滴眼液,观察组患者在对照组基础上给予贝复舒滴眼液。比较两组患者临床疗效、眼部炎症消退时间,并观察两组患者不良反应发生情况。结果观察组患者总有效率高于对照组,眼部炎症消退时间短于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论糖皮质激素联合贝复舒滴眼液治疗EKC的临床疗效确切,可快速消退眼部炎症,且安全性较高。Objective To investigate the clinical efficacy and safety of glucocorticoid combined with befushu eye drops for EKC.Methods A total of 75 patients with EKC were selected from 2017 in Department of ophthalmology,Sheyang Renai ENT Hospital,which were divided into control group(n=37)and observation group(n=38)according to random number table method.The control group were given glucocorticoid tobramycin and dexamethasone eye drops based on routine treatment,while the observation group were given befushu eye drops based on control group.The clinical efficacy and the time of eye inflammation subsidence between the two groups were compared,and the adverse reactions of the two groups were observed. Results The observation group of total effective rate was higher than control group,and the time of eye inflammation subsidence was shorter than control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Glucocorticoid combined with beifushu eye drops has definite clinical efficacy for EKC,it can quickly eliminate eye inflammation,and with high safety.

关 键 词：角结膜炎 地塞米松滴眼液 治疗结果 

分 类 号：R777.31[医药卫生—眼科] R772.21[医药卫生—临床医学]